Muhammed Kotan is an Assistant Professor at the Department of Information Systems Engineering , Sakarya University , where he has served since 2022. His academic career includes roles as a Research Assistant (2011–2022) at Sakarya University and Afyon Kocatepe University. He holds a PhD in Computer and Information Engineering (2020), an MSc in Computer and Information Engineering (2014), and a BSc in Computer Engineering (2011) from Sakarya University. Research Interests : Artificial Intelligence, Computer Software, Image Processing, Machine Learning, Computer Vision, Medical Imaging, Energy Efficiency Optimization, Natural Language Processing, Sentiment Analysis, Feature Selection, 3D Reconstruction, Industrial Machine Detection, Optimization Algorithms, Real-Time Systems, User Reviews Analysis, E-Commerce Analytics. Key Contributions : Developed hybrid methods for 3D reconstruction and industrial machine defect detection, optimized tow train routing in manufacturing, and applied Marine Predators Algorithm for mental health screening. Scientific Recognition : Awarded the Eğitim Öğretimde Üstün Başarı Ödülü by Sakarya University (2024). Served as editor for the Sakarya University Journal of Computer and Information Sciences (2023–2024) and peer reviewer for journals like Signal, Image and Video Processing and Gazi Üniversitesi Mühendislik Mimarlık Fakültesi Dergisi . Advising : Co-advisor for TÜBİTAK projects (2022–2024) and supervised student research on topics like cosmetic product recognition, natural language processing, and sentiment analysis. Designed courses in Digital Image Processing, Text Mining, and Advanced Information Systems.
Valentina Noemi Madia is a Researcher (RTD-A) at Sapienza University of Rome, Department of Chemistry and Technologies of Drugs, where she focuses on the design and synthesis of small molecules active against emerging viruses. She has been with the university since completing her PhD in 2017 and has established herself as a prominent researcher in medicinal chemistry with over 43 peer-reviewed publications, one international patent, and one book chapter. Her educational background includes: PhD in Life Sciences (with mark "Excellent") from Sapienza University of Rome (2017) Master's Degree in Pharmacy (110/110 summa cum laude) from Sapienza University of Rome (2013) Qualification for the practice of the pharmacist profession (2014) Dr. Madia's research centers on the design and development of heterocyclic small molecules with diverse biological activities. Her work spans multiple therapeutic areas including antiviral agents (targeting HIV, coronaviruses, HCV, polio, and influenza), antifungal, antibacterial, antiprotozoal, anticancer, and anti-Alzheimer agents. She employs modern drug design approaches such as computer-aided drug design, parallel synthesis, and green chemistry techniques including microwave-assisted and flow chemistry synthesis. Her publication record shows a strong focus on antiviral drug development, particularly against HIV and SARS-CoV-2, with numerous articles on structure-activity relationships of heterocyclic compounds. She has also made significant contributions to the development of antiprotozoal, anticancer, and antifungal agents, demonstrating the breadth of her expertise in medicinal chemistry. Dr. Madia has received several prestigious awards for her work: Best Poster Presentation Prize from the European Federation of Medicinal Chemistry (2024) Medicinal Chemistry Division Prize from the Italian Chemical Society (2024) Premio Soroptimist 2021 for the best research project Multiple travel grants from the Italian Chemical Society for national and international meetings As an educator, Dr. Madia serves as a teacher for "Fundamentals of Chemical Biology I" and has supervised numerous undergraduate and PhD students since 2017. She has secured research funding as both principal investigator and participant, including projects focused on HIV-1 ribonuclease H inhibitors and SARS-CoV-2 protease inhibitors. Her service to the scientific community includes membership on the Topical Advisory Panel for Pharmaceuticals journal and peer reviewing for multiple scientific publications.
Professor Robert Newton is a distinguished academic at the University of Calgary, holding a professorship in the Department of Physiology and Pharmacology within the Cumming School of Medicine. He maintains multiple significant research affiliations including as a Full Member of the Calvin, Phoebe and Joan Snyder Institute for Chronic Diseases, a Child Health & Wellness Researcher at the Alberta Children's Hospital Research Institute, and a Full Member of the Inflammation Research Network. His work is centrally focused on understanding the molecular mechanisms underlying respiratory inflammatory diseases, particularly asthma and COPD. Newton earned his B.Sc. in Biochemistry from Imperial College of Science and Technology, London (1987) followed by a Doctor of Philosophy in Molecular Genetics from the Royal Postgraduate Medical School, University of London (1992). His educational foundation in molecular biology and biochemistry has directly informed his research trajectory in pulmonary pharmacology and inflammation. Professor Newton's research program centers on the molecular mechanisms of glucocorticoid action in the treatment of airway inflammation. His work specifically investigates how glucocorticoids (corticosteroids) function as anti-inflammatory agents in asthma treatment and why combination inhalers containing both glucocorticoids and long-acting β2-adrenoceptor agonists (LABAs) demonstrate enhanced clinical efficacy. The Newton lab pursues several interconnected research threads: mechanisms of anti-inflammatory glucocorticoid action; enhancement of glucocorticoid action by LABAs; NF-κB as a target for novel anti-inflammatory drugs; alternative signal transduction pathways for NF-κB-dependent inflammatory gene expression; and aspects of cAMP signaling pathway regulation and function. His work has important implications for developing improved combination therapies for respiratory diseases. Analysis of Newton's recent publications (2018-2025) reveals a consistent focus on the genomic and molecular interactions between glucocorticoids and β2-agonists in airway epithelial cells. His research increasingly employs transcriptomic approaches to understand gene expression changes, with particular attention to NF-κB signaling, cAMP pathways, and transcriptional regulation. A notable trend is the exploration of compartmentalized signaling and gene-specific mechanisms rather than generic effects, suggesting a move toward more targeted therapeutic approaches. His work bridges basic molecular mechanisms with clinical applications in respiratory medicine. Alberta Innovates Award (2013) Alberta Innovates Award (2009) Scholarship (2009) The Lung Association - Alberta and North West Territories Award (2009) Salary Support Award (1995) As part of the Airways Inflammation Research Group (formerly the Respiratory Research Group), Professor Newton collaborates extensively with other researchers including Prof. Mark Giembycz to examine the molecular basis for the enhancement of glucocorticoid action by LABAs. His research has been supported by various grants from Alberta Innovates and The Lung Association. Newton's work contributes significantly to the University of Calgary's Child Health and Wellness strategic initiative (2020-2025). His research program represents a substantial investment in understanding the fundamental mechanisms of respiratory disease treatment, with potential applications for improving therapeutic approaches for millions suffering from asthma and COPD. Professor Newton leads an active research laboratory focused on airway inflammation mechanisms. His team employs molecular, cellular, and genomic approaches to investigate glucocorticoid and β2-agonist signaling in airway epithelial cells. The lab's work is highly collaborative, involving partnerships across the Cumming School of Medicine and with clinical researchers at the Alberta Children's Hospital. Newton's research group represents a significant hub for pulmonary pharmacology research in Canada, contributing to both fundamental scientific understanding and potential clinical applications in respiratory medicine.
Büşra Şen Halicioğlu is an Assistant Professor in the Department of Basic Medical Sciences at the Faculty of Medicine, Gaziantep University, a position she has held since 2022. Previously, she served as a Research Assistant at Gaziantep University (2013-2016, 2018-2022) and Celal Bayar University (2016-2018). Her educational background includes: Doctorate in Histology and Embryology from Manisa Celal Bayar University (2016-2020) Master of Science in Histology and Embryology from Gaziantep University (2013-2015) Bachelor of Science in Biology from Fatih University (2007-2012), completed on a full scholarship Dr. Şen Halicioğlu's research focuses on stem cell therapy for reproductive disorders, particularly premature ovarian failure, and the protective effects of natural compounds such as curcumin against chemotherapy-induced organ toxicity. Her work employs animal models to study ovarian function, nephrotoxicity, and hepatotoxicity, with additional investigations into molecular mechanisms in cancer cell lines and gap junction dynamics. Analysis of her 2020-2021 publications reveals dominant trends in regenerative medicine applications for reproductive health, featuring adipose-derived stem cells as a primary therapeutic approach for ovarian insufficiency. Concurrently, her research demonstrates significant emphasis on phytochemical interventions, particularly curcumin, for mitigating cisplatin-induced damage in renal and hepatic tissues through antioxidant pathways. Scientific Awards: 2017 University Best Scientific Work Award from Abdullah Gül University Dr. Şen Halicioğlu teaches undergraduate courses in Histology and Embryology for the Nursing Department and participates in medical curriculum committees covering foundational life sciences through endocrine and urogenital systems. Her research portfolio includes five national projects: Effect of Curcumin on Cisplatin-Induced Kidney Damage in Rats (2016) Efficacy of Stem Cell Treatment in Experimental Premature Ovarian Failure Models (2019-2020) Effect of Curcumin on Cisplatin-Induced Liver Damage in Rats (2015-2016) Investigation of Curcumin's Effects on Akt, FoxO3a, and Bim Pathways in Human Glioblastoma Cell Lines (2021-2022) Investigation of Moringa oleifera's Effects on Akt, FoxO3a, and Bim Pathways in Human Glioblastoma Cell Lines (2021-2022) She actively collaborates with interdisciplinary research teams in stem cell biology and toxicology, maintaining professional memberships in the Turkish Biochemistry Association (since 2019) and the Turkish Histology and Embryology Association (since 2016).
Dr. Keykavous Parang is a Professor at Chapman University with dual appointments in the School of Pharmacy and the Schmid College of Science and Technology. His expertise spans medicinal chemistry, drug delivery, and peptide nanotechnology, making significant contributions to both academic and pharmaceutical research fields. Dr. Parang has established himself as a leader in peptide-based drug delivery systems and antimicrobial research. Education: Doctor of Pharmacy from Tehran University of Medical Sciences (1989) Ph.D. in Medicinal Chemistry from University of Alberta, Canada (1997) Postdoctoral studies at University of Alberta, Rockefeller University, and Johns Hopkins University Research Interests: Dr. Parang's research focuses on the intersection of chemistry and biology, particularly on medicinal chemistry, organic chemistry, nanomedicine, and drug delivery. His work involves applying synthetic organic chemistry to biological challenges. Current research areas include utilizing cyclic and hybrid cyclic-linear peptides for drug delivery, designing peptides with antibacterial and antifungal properties, developing multifunctional agents with antiviral, anticancer, and antibacterial activities, and creating inhibitors for protein tyrosine kinases. His laboratory has made significant contributions to peptide-based drug delivery systems and antimicrobial peptide research. Publication Trends: Dr. Parang's recent publications (2024-2025) demonstrate a strong focus on peptide-based drug delivery systems, particularly cyclic and amphiphilic peptides for antimicrobial applications, cancer therapy, and nucleic acid delivery. His work shows increasing interdisciplinary collaboration across chemistry, biology, and pharmacology, with a growing emphasis on translational research that bridges basic science with clinical applications. The trend indicates expanding applications of peptide technology in addressing drug resistance challenges across multiple therapeutic areas. Scientific Awards: Academy of Pharmacy Professionals (APP) Academic Excellence Award (2024) Chapman University Million Dollar Club (2022) CUSP Culture Award: Diversity and Inclusion (2021) AIMS Award (2021) AACP Catalyst Program (Accelerating Research Leadership, 2017-2018) AACP Catalyst Program Fellowship (2017) AACP Teacher of the Year (2015) Listed among world's career top 2% of scientists by Stanford University (September 16, 2024) Top 12 Scientists at Chapman University (AD Scientific Index 2025) Advising and Grants: Dr. Parang has guided numerous faculty members and has supervised 25+ postdoctoral fellows and visiting scientists. Additionally, he has mentored 30+ graduate students and 65+ undergraduate students. His laboratory has been funded with $6.59 million from NIH, American Cancer Society, NSF, Industry, USAID-CONRAD, Kay Foundation, and many other funding agencies since October 2000. His research program demonstrates consistent funding success across multiple federal and private sources. Laboratories and Research Teams: Dr. Parang leads a multidisciplinary research group focusing on peptide chemistry and drug delivery systems. His laboratory has established infrastructure for peptide synthesis, characterization, and biological evaluation. The team includes graduate students, postdoctoral fellows, and undergraduate researchers working collaboratively on various aspects of peptide-based therapeutics. His leadership has helped establish research infrastructure and core facilities at Chapman University's School of Pharmacy.
Dr. Andreas Feigenspan is a Professor of Neurobiology at the Department of Biology, Friedrich-Alexander University Erlangen-Nürnberg. Based in Erlangen, Germany (Room 00.144, Building A1), he focuses on retinal physiology, synaptic transmission, and ion channel dynamics through experimental and computational approaches. Research Interests: Neurobiology, Retinal Physiology, Synaptic Transmission, Ion Channels, Neural Networks, and Machine Learning applications in neuroscience. Key Research Themes: His work explores molecular mechanisms in retinal signal processing, calcium channel modulation in oligodendrocytes, synaptic plasticity in photoreceptor networks, and computational models of neural circuits. Recent Article Trends: Analysis of voltage-gated channels, synaptic protein disruptions (e.g., Bassoon), machine learning applications in synaptic current detection, and comparative studies between biological and artificial neural networks. Contact: Email andreas.feigenspan@fau.de or visit the Neurobiology Research Group website.
Donatella Ponti is a Researcher (RU) in the Department of Medical-Surgical Sciences and Biotechnologies at the University of Rome "Sapienza," specializing in MEDS-02/A (MED04) General Pathology. She serves as President of the Course in Childhood Neuro and Psychomotricity and is responsible for courses in Molecular Oncology and Molecular Pathology at the Medical Faculty. Her academic career spans over two decades with a permanent research position since December 2010. Dr. Ponti earned her PhD in Biochemistry from University La Sapienza di Roma (1998-2001) under Prof. D. Barra. Prior to this, she completed a School in Biotechnology (summa cum laude) at University of Rome La Sapienza and a Biological Sciences Degree (summa cum laude) from University "La Sapienza" Rome. Her research focuses on molecular mechanisms of disease, particularly nuclear and nucleolar trafficking, protein expression, and DNA manipulation. She investigates the nucleolus as a central hub in cancer proliferation, with emphasis on receptors and transcriptional factors that modulate cell proliferation through nucleolar metabolism. Her work bridges molecular biology, cancer research, and cellular signaling pathways, with particular interest in ErbB3 receptor signaling and its nucleolar localization in glioblastoma. The thematic areas of her research include Biotechnology, Molecular Biology, Biochemistry, Cell Pathology, nucleolar metabolism, immunometabolism, and ribosome biogenesis. Her publication record demonstrates a clear trajectory from fundamental molecular biology toward translational cancer research. Early work focused on ribosomal RNA processing and antimicrobial peptides, while more recent publications center on nucleolar metabolism in cancer cells, macrophage cross-talk in tumor microenvironments, and therapeutic targeting of nucleolar dysfunction. A consistent theme across her 31 publications is the exploration of non-canonical pathways involved in cancer proliferation under nucleolar control. Dr. Ponti has received recognition for her scientific contributions: DAAD Fellowship (2017) for research at Heidelberg University Award for thesis in Biotechnology from University of Rome Sapienza (1997) Member of National Register of Biologist (since 2009) As an academic advisor, Dr. Ponti has supervised numerous graduate students including Federico Forzati, Aurora Mosetti, Selenia di Rosa, and Marzia Tagliaferro. Her research has been supported by multiple competitive grants including Sapienza University funding (2015-2024), MIUR funding, and a DAAD scholarship. She currently serves as Principal Investigator for projects including "Fibrillarin and the Nucleolus in Human Macrophage Polarization" and "Nucleolar ErbB3: A NEW TARGET IN GLIOBLASTOMA." Dr. Ponti leads research in the Instrumental Laboratory at the Department of Medical-Surgical Science and Biotechnologies and has previously supervised the animal laboratory at the same department. Her laboratory investigates cellular models including cell lines and mouse models to study molecular mechanisms of disease, with particular focus on nucleolar metabolism in cancer contexts.
Benjamin L. Maughan, MD, PharmD serves as Associate Professor in the Division of Medical Oncology within the Department of Internal Medicine at the University of Utah's Huntsman Cancer Institute. His clinical focus centers on genitourinary malignancies with appointments at Farmington Health Center and Huntsman Cancer Institute. His educational background includes: PharmD, cum laude from Idaho State University College of Pharmacy (2004) Oncology Pharmacy Residency at St. Luke's Mountain States Tumor Institute (2005) MD, cum laude from University of Kentucky College of Medicine (2010) Internal Medicine Residency at University of Utah School of Medicine (2013) Medical Oncology Fellowship at Johns Hopkins University (2016) Dr. Maughan's research concentrates on predictive biomarker development and novel therapeutics for genitourinary cancers, particularly metastatic prostate, kidney, and bladder cancers. His work explores immune therapy combinations including checkpoint inhibitors with radiation therapy (radium-223), oncolytic viruses (MVA-brachyury), and targeted therapies (cabozantinib). He investigates truncated androgen receptors (AR-V7) and tumor suppressor loss (PTEN/Rb) as biomarkers in prostate cancer. His recent publications demonstrate strong focus on biomarker validation, immunotherapy combinations, and real-world treatment patterns across genitourinary malignancies, with particular emphasis on renal cell carcinoma and prostate cancer subtypes. Current research trends show increasing integration of genomic profiling with clinical outcomes assessment. Scientific recognition includes: Huntsman Cancer Institute Translational Scholar Award (2019) SWOG Young Investigator Training Course selection (2019) Dr. Maughan leads clinical trials including a SWOG study exploring novel treatments for metastatic papillary kidney cancer. His patient care philosophy emphasizes detailed explanation and compassionate communication, reflected in consistently high patient satisfaction scores (4.9/5 from 256 reviews). He holds board certifications in Internal Medicine and Medical Oncology from the American Board of Internal Medicine.
Xun Li is an Associate Professor in the Department of Medicinal Chemistry at the School of Pharmaceutical Science, Shandong University. She has been affiliated with the institution since 2004, holding roles as Lecturer, Postdoctoral Fellow, and Associate Professor. Education: Ph.D. in Chemistry from Shandong University and Tianjin University (2004), B.S. in Chemistry from Qufu Normal University (1999). Professional Experience: 2004-2006 Lecturer & Postdoctoral Fellow; 2006-present Associate Professor; Visiting Scholar at Tokyo University (2007, 2008). Her research focuses on anti-tumor agents , peptidomimetics , multidrug resistance (MDR) reversal , matrix metalloproteinase (MMP) inhibitors , and aminopeptidase N (APN) inhibitors . She has published extensively on quinoxalinone derivatives and their roles in cancer therapy. Scientific Awards include: Excellent Postdoctoral Research Fellowship of China (2005) Youth Research Fellowship of 40th IUPAC (2005) Second-Class Shandong Province Science and Technology Progress Award (2012) She has secured multiple grants , including National Natural Foundation Research Grants and Japan-China Collaborative Research Grants, and holds several patents for quinoxalinone derivatives with MDR reversal and MMP inhibition activity.
Swarna Basu is Professor and Head of the Department of Chemistry at Susquehanna University, where she has held progressive faculty positions since 2005 (Assistant Professor 2005-2011, Associate Professor 2011-2016, Professor 2016-present). She holds a PhD and MA from Wesleyan University and a BA from Clark University. Education PhD, Wesleyan University MA, Wesleyan University BA, Clark University Research Focus Dr. Basu leads an interdisciplinary physical/biophysical chemistry research program with three core themes: 1) Synthesis and functionalization of metallic nanoparticles (Au, Ag, ZnO) via conventional and green methods for biological applications including antibacterial agents, dye degradation, and Raman enhancement; 2) Protein/polymer cross-linking for smart biomaterials and drug delivery systems; 3) Spectroscopy-based investigations of metal complex interactions with proteins and DNA structures. Her work emphasizes instrument development, including custom microscopy and LabVIEW-based photochemical systems. Publication Analysis Her recent work (2012-2025) demonstrates strong focus on nanomaterial applications in biomedicine (cancer therapy, immunomodulation) and DNA biochemistry, particularly quadruplex DNA interactions with neurotransmitters/metal complexes. Methodologies frequently combine fluorescence/Raman spectroscopy with computational modeling, reflecting her physical chemistry expertise. Awards and Recognition John C. Horn Distinguished Service Award (2015) Invited Public Lecture: "Size Matters: Tiny Dots and Their Potential" (2016) Tishler Teaching Award (2002) Teaching and Mentoring She teaches undergraduate courses including General Chemistry, Physical Chemistry, Nanoscience, and research seminars. Actively mentors undergraduate researchers, with collaborative projects frequently resulting in co-authored publications and conference presentations.
Bryan Phillips is a Professor in the Department of Biology at the University of Iowa, where he conducts research on cell fate determination and developmental biology using C. elegans as a model organism. His work focuses on understanding how a single undifferentiated oocyte develops into a multicellular organism with numerous, intricately connected cell types through precise molecular mechanisms. Dr. Phillips received his PhD from Texas A&M University. His research primarily investigates the molecular mechanisms of cell-to-cell communication during development, with a particular emphasis on the Wnt signaling pathway and its role in asymmetric cell division where a polarized mother cell generates two daughter cells with different fate determinants. Dr. Phillips' laboratory examines how the Wnt signaling pathway regulates cell fate through β-catenin, with a special focus on SYS-1, a β-catenin homolog in C. elegans that shares structural and functional similarities with vertebrate β-catenin. His research explores how centrosomes, protein degradation mechanisms, and gene duplication events contribute to the regulation of asymmetric cell divisions. The lab's work bridges molecular, cellular, and developmental biology to address fundamental questions about why animal cells differentiate the way they do, with implications for developmental defects and diseases like cancer where Wnt signaling is often misregulated. Analysis of Dr. Phillips' publication record reveals a consistent research trajectory focused on Wnt signaling, β-catenin regulation, and asymmetric cell division across 15 recent publications (2015-2025). His work demonstrates how conserved molecular mechanisms control cell fate determination, with particular attention to the SYS-1 protein and its regulation through centrosomal localization, proteasomal degradation, and transcriptional activation. The research spans multiple levels of investigation from protein structure and evolutionary analysis to developmental processes in a whole organism. Dr. Phillips' laboratory is actively recruiting graduate students through multiple programs including the UI Biology Department, the UI Genetics Program, the UI Molecular and Cellular Biology Program, and the UI Biosciences Program. His research facilities are located in the Biology Building East (BBE) at the University of Iowa, where he maintains both office space (200 BBE) and laboratory facilities with dedicated phone lines for administrative and research communications.
Hanne Røberg-Larsen is an Associate Professor at the University of Oslo, positioned within the Section for Chemical Life Sciences – Biomolecules, Bio-Inspired Materials and Bioanalytical Chemistry. Her work sits at the intersection of advanced analytical chemistry and biomedical research, where she develops and applies cutting-edge LC-MS technologies to address complex biological questions. Research Focus: Bioanalytical method development using nano- and capillary-LC–MS Oxysterol biology and lipid signalling in cancer and metabolic disease Single-cell and ultra-small sample omics Organoid and organ-on-chip analytics Automated sample preparation and microfluidic integration Across more than 40 peer-reviewed papers (2012-2025), her group has progressively pushed sensitivity limits for detecting metabolites, hormones and drugs in miniaturised systems. Recent trends reveal a strong emphasis on in vitro microphysiological models—combining organoids, organ-on-chip devices and tailored LC-MS workflows—to study metabolic crosstalk and therapeutic responses under controlled conditions. Particular attention is given to cholesterol-derived signalling molecules (oxysterols) and their impact on breast cancer chemoresistance and non-alcoholic fatty liver disease. Collaborative Environment: She participates in the strategic research initiative “Integrated technologies for tracking organoid morphogenesis (ITOM)” and is affiliated with the Bio3 research group “Chemical Life Sciences – Biomolecules, Bio-Inspired Materials and Bioanalytical Chemistry”. The group fosters interdisciplinary collaborations bridging chemistry, biology and engineering. No explicit funding details, awards or student lists were present in the supplied material.
Satoshi Yano is an Assistant Professor (non-tenure-track) at Waseda University's Faculty of Human Sciences, specializing in the molecular mechanisms of food functionality with applications in health promotion and disease prevention. His research integrates food science, molecular biology, and cellular mechanisms to elucidate how dietary components influence cellular processes relevant to aging and health. Dr. Yano's research interests focus on food molecular functionality, health science, nutrigenetics, bioinformatics, functional foods, autophagy, and exosomes. His work primarily investigates how specific food compounds—including wasabi components, fermented garlic, plant polyphenols, and D-amino acids—affect cellular processes such as autophagy, proteostasis, stress responses, and cell signaling pathways. His approach combines omics technologies, cell culture models, and molecular techniques to uncover the mechanisms by which food components exert their biological effects. Analysis of his publication record reveals a strong focus on autophagy regulation by food components, with significant contributions to understanding how dietary factors influence cellular homeostasis, stress response, and aging-related processes. His work spans multiple disciplines including food science, molecular biology, dermatology, and cancer research, demonstrating the interdisciplinary nature of his research on food functionality. Dr. Yano has received numerous scientific awards including the Encouragement Award from the International Taurine Research Society Japan Division (2025), multiple presentation awards at food science conferences, and prestigious university honors from Kagoshima University. His research has been supported by competitive grants from the Japan Society for the Promotion of Science and Waseda University's research foundation. As an educator, Dr. Yano teaches courses in Data Literacy, Student Life and Self-Management, Study Skills, and Basic Seminar II at Waseda University's School of Human Sciences. He also serves on various academic committees including the Secretariat of the 45th Joint Symposium of the Japan Society for Basic Gerontology and the Food for Health International Conference Executive Committee.
Clinical Professor Paul Robinson is a leading clinician-researcher at the University of Sydney's Discipline of Paediatrics and Child Health , with clinical specialization at The Children's Hospital at Westmead and research affiliations with the Woolcock Medical Research Institute . As Director of the Australian Central Over-Reading Centre (CORC) network, he standardizes Multiple Breath Washout (MBW) and Oscillometry testing globally. His work bridges clinical practice and translational research in pediatric respiratory medicine. Member of Charles Perkins Centre International collaborations with University of Toronto , Central Hospital Skovde , and Royal Brompton Hospital Research Interests : Targeting early detection of peripheral airway disease in pediatrics using MBW and Oscillometry —tools that assess nearly 95% of lung volume previously considered 'silent.' These methods are feasible across all pediatric ages and form the basis for clinical translation in Cystic Fibrosis , Asthma , and Post-Transplantation Monitoring . His team explores structure-function relationships through CT and MRI integration. Article Trends (2013–2025) show sustained focus on MBW/Oscillometry standardization, pediatric respiratory disease mechanisms, and clinical translation. Key areas include CF lung disease , asthma control , and environmental health impacts like bushfire smoke. Collaborations span Canada , Sweden , and UK . Scientific Awards include multiple TSANZ and ANZSRS best presentation awards (2006–2021), NHMRC PhD scholarship (2008), and leadership recognition through ATS Paediatric Assembly Chair roles. Teaching & Supervision involves medical students, junior staff training, and higher research candidates. Current Projects (2015–2025) span NHMRC , Asthma Australia , and Sydney Medical School Foundation grants, focusing on maternal asthma effects , home-based asthma monitoring , and post-transplantation complications .
Christopher Gerner is a Professor at the University of Vienna, holding positions in the Faculty of Chemistry, Institute of Analytical Chemistry, Department of Microbiology and Ecosystem Research, and Center for Microbiology and Environmental Systems Science. He directs the Mass Spectrometry Center and maintains an active research program spanning proteomics, metabolomics, and lipidomics with applications in cancer research and drug development. His research focuses on Proteomics , Mass Spectrometry , Cancer Research , Metabolomics , Lipidomics , and Systems Biology , with particular expertise in cancer cell biology, tumor microenvironment, and drug mechanism studies. His work contributes significantly to understanding ovarian cancer, metastatic melanoma, and inflammatory responses through multi-omics approaches. Dr. Gerner's publication record shows consistent productivity with over 245 publications spanning from 2008 to present, with recent work increasingly focusing on morphometabolic fingerprinting of ovarian cancer, PFAS toxicity, and the biophysical properties of tumor microenvironments. His research integrates proteomics with metabolomics to provide comprehensive molecular insights into disease mechanisms. Best Poster Preis - HPLC 2017: 45th International Symposium on High Performance Liquid Phase Separations and Related Techniques (June 18, 2017) Best Poster Prize - Symposium 'Advances in Chromatography and Electrophoresis & Chiranal 2018' (January 29, 2018) Dr. Gerner leads the ongoing research project 'Morphometabolic fingerprint of ovarian cancer' (2022-2026) in collaboration with Del Favero, Köllensperger, and Zanghellini. His laboratory activities include the Mass Spectrometry Center which serves as a hub for proteomics and metabolomics research at the University of Vienna, supporting both basic and translational research projects across multiple disciplines.
